Favorable Macroeconomic and Healthcare Trends to Accelerate the Malaysian Pharmaceutical Market, Finds Frost & Sullivan
For foreign investors, collaborations with domestic participants may prove necessary for market entry
KUALA LUMPUR, Malaysia, Oct. 7, 2015 /PRNewswire/ -- Malaysia's policies that encourage domestic investments and local consumption are driving up its gross domestic product (GDP). This promising investment climate, coupled with citizens' rising willingness to pay out-of-pocket for expensive drugs, has allowed the country to improve medical access and provide pharmaceutical companies with significant revenue-generating opportunities.
New analysis from Frost & Sullivan, Analysis of the Pharmaceutical Market in Malaysia (http://www.frost.com/q294996268), explores the broad competitive landscape, demand dynamics and regulatory environment that are relevant to investors. The pharmaceutical market is expected to demonstrate double-digit growth rate from 2010 to 2020 due to a prospering economy, improved drug regulations, wider healthcare provision, medical tourism and modernization.
For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/SEA_PR_DJeremiah_9AB9_1Sept15
"Malaysia is emerging a hot favorite among investors in the pharmaceutical market due to its expanding population base and the increasing life expectancy of its citizens," remarked Frost & Sullivan Healthcare Research Analyst Rageshwary Ramupillai. "Indeed, the growing number of people aged 65 and above is intensifying the demand for quality healthcare services in the country."
The Government has thrown its weight behind the market with the Entry Project Point (EPP3) under the Healthcare National Key Economic Area (NKEA). This flexible regulatory landscape enhances the scope for both local and international investment in the pharmaceutical market.
"While on the one hand, the policies under the Healthcare NKEA encourage Malaysian companies to make and export generic drugs, on the other, the protection of the local drug manufacturing companies hinders the entry of foreign players," observed Rageshwary. "Therefore, partnerships with the domestic drug manufacturers and distributors along with acquisitions are important for a quick entry to the market."
Furthermore, the Malaysian pharmaceutical market is bolstered by its reputation as one of the world's leading exporters of halal ingredients required in various industries. This has placed it on path to becoming a top global participant in the manufacture and certification of halal medicines.
Overall, a vibrant economy, swelling patient pool and solid government backing are boosting the prospects of pharmaceutical companies in Malaysia, as well as creating opportunities for foreign investors seeking to establish a footprint in the country.
Analysis of the Pharmaceutical Market in Malaysia is part of the Life Sciences (http://ww2.frost.com/research/industry/healthcare/life-sciences) Growth Partnership Service program. Frost & Sullivan's related studies include: APAC CRO Market, Major Attractions of the Global Aged Care Market, Analysis of the Global Oncology Drug Delivery Market, Indonesia Healthcare Outlook. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Analysis of the Pharmaceutical Market in Malaysia
9AB9
Contact:
Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: [email protected]
Carrie Low
Corporate Communications – Asia Pacific
P: +603 6204 5910
F: +603 6201 7402
E: [email protected]
Melissa Tan
Corporate Communications – Asia Pacific
P: +65 6890 0926
F: +65 6890 0999
E: [email protected]
Share this article